Perceptions and Preoccupations of Patients and Physicians Regarding Use of Medical Cannabis as an Intervention Against Chronic Musculoskeletal Pain: Results from a Qualitative Study

References

• Arthritis Society. Arthritis in Canada. Facts & Figures. The Arthritis Society of Canada; 2015.
   Google Scholar
• Moore RA, Derry S, Taylor RS, Straube S, Phillips CJ. The costs and consequences of adequately managed chronic non-cancer pain and chronic neuropathic pain. Pain Pract. 2014;14(1):79–94. doi:10.1111/papr.12050
   PubMed Web of Science ®Google Scholar
• World Health Organisation, Bank TW. World report on disability; 2011.
   Google Scholar
• Yelin E, Weinstein S, King T. The burden of musculoskeletal diseases in the United States. Semin Arthritis Rheum. 2016;46(3):259–260. doi:10.1016/j.semarthrit.2016.07.013
   PubMed Web of Science ®Google Scholar
• van Erp RMA, Huijnen IPJ, Jakobs MLG, Kleijnen J, Smeets R. Effectiveness of primary care interventions using a biopsychosocial approach in chronic low back pain: a systematic review. Pain Pract. 2019;19(2):224–241. doi:10.1111/papr.12735
   PubMed Web of Science ®Google Scholar
• Fitzcharles MA, Baerwald C, Ablin J, Hauser W. Efficacy, tolerability and safety of cannabinoids in chronic pain associated with rheumatic diseases (fibromyalgia syndrome, back pain, osteoarthritis, rheumatoid arthritis): a systematic review of randomized controlled trials. Schmerz. 2016;30(1):47–61. doi:10.1007/s00482-015-0084-3
   PubMed Web of Science ®Google Scholar
• Goldenberg DL, Clauw DJ, Fitzcharles MA. New concepts in pain research and pain management of the rheumatic diseases. Semin Arthritis Rheum. 2011;41(3):319–334. doi:10.1016/j.semarthrit.2011.04.005
   PubMed Web of Science ®Google Scholar
• Petzke F, Enax-Krumova EK, Hauser W. Wirksamkeit, Verträglichkeit und Sicherheit von Cannabinoiden bei neuropathischen Schmerzsyndromen [Efficacy, tolerability and safety of cannabinoids for chronic neuropathic pain: a systematic review of randomized controlled studies]. Der Schmerz. 2016;30(1):62–88. German. doi:10.1007/s00482-015-0089-y
   PubMedGoogle Scholar
• Schaefert R, Welsch P, Klose P, Sommer C, Petzke F, Hauser W. Opioide bei chronischem Arthroseschmerz Systematische Übersicht und Metaanalyse der Wirksamkeit, Verträglichkeit und Sicherheit in randomisierten, placebokontrollierten Studien über mindestens 4 Wochen[Opioids in chronic osteoarthritis pain. A systematic review and meta-analysis of efficacy, tolerability and safety in randomized placebo-controlled studies of at least 4 weeks duration]. Schmerz. 2015;29(1):47–59. German. doi:10.1007/s00482-014-1451-1
   PubMed Web of Science ®Google Scholar
• Atluri S, Sudarshan G, Manchikanti L. Assessment of the trends in medical use and misuse of opioid analgesics from 2004 to 2011. Pain Phys. 2014;17(2):E119–28. doi:10.36076/ppj.2014/17/E119
   PubMed Web of Science ®Google Scholar
• Ballantyne JC. Opioid therapy in chronic pain. Phys Med Rehabil Clin N Am. 2015;26(2):201–218. doi:10.1016/j.pmr.2014.12.001
   PubMed Web of Science ®Google Scholar
• Hauser W, Petzke F, Radbruch L, Tolle TR. The opioid epidemic and the long-term opioid therapy for chronic noncancer pain revisited: a transatlantic perspective. Pain Manag. 2016;6(3):249–263. doi:10.2217/pmt.16.5
   PubMedGoogle Scholar
• Tobin DG, Andrews R, Becker WC. Prescribing opioids in primary care: safely starting, monitoring, and stopping. Cleve Clin J Med. 2016;83(3):207–215. doi:10.3949/ccjm.83a.15034
   PubMed Web of Science ®Google Scholar
• Rowe J, Caprio AJ. Chronic pain: challenges and opportunities for relieving suffering. N C Med J. 2013;74(3):201–204. doi:10.18043/ncm.74.3.201
   PubMedGoogle Scholar
• Gereau RW, Sluka KA, Maixner W, et al. A pain research agenda for the 21st century. J Pain. 2014;15(12):1203–1214. doi:10.1016/j.jpain.2014.09.004
   PubMed Web of Science ®Google Scholar
• Lynch ME, Ware MA. Cannabinoids for the treatment of chronic non-cancer pain: an updated systematic review of randomized controlled trials. J Neuroimmune Pharmacol. 2015;10(2):293–301. doi:10.1007/s11481-015-9600-6
   PubMed Web of Science ®Google Scholar
• McDonagh MS, Wagner J, Ahmed AY, et al. Living Systematic Review on Cannabis and Other Plant-Based Treatments for Chronic Pain. Rockville, MD: Agency for Healthcare Research and Quality; 2022.
   Google Scholar
• Elikottil J, Gupta P, Gupta K. The analgesic potential of cannabinoids. J Opioid Manag. 2009;5(6):341–357. doi:10.5055/jom.2009.0034
   PubMedGoogle Scholar
• Boehnke KF, Litinas E, Clauw DJ. Medical cannabis use is associated with decreased opiate medication use in a retrospective cross-sectional survey of patients with chronic pain. J Pain. 2016;17(6):739–744. doi:10.1016/j.jpain.2016.03.002
   PubMed Web of Science ®Google Scholar
• Kröger E, Dionne CE. Medical cannabis for chronic pain. BMJ. 2021;374:n1942. doi:10.1136/bmj.n1942
   PubMedGoogle Scholar
• Whiting PF, Wolff RF, Deshpande S, et al. Cannabinoids for medical use: a systematic review and meta-analysis. JAMA. 2015;313(24):2456–2473. doi:10.1001/jama.2015.6358
   PubMed Web of Science ®Google Scholar
• Fitzcharles MA, Ste-Marie PA, Hauser W, et al. Efficacy, tolerability, and safety of cannabinoid treatments in the rheumatic diseases: a systematic review of randomized controlled trials. Arthritis Care Res. 2016;68(5):681–688. doi:10.1002/acr.22727
   PubMed Web of Science ®Google Scholar
• Stockings E, Campbell G, Hall WD, et al. Cannabis and cannabinoids for the treatment of people with chronic noncancer pain conditions: a systematic review and meta-analysis of controlled and observational studies. Pain. 2018;159(10):1932–1954. doi:10.1097/j.pain.0000000000001293
   PubMed Web of Science ®Google Scholar
• Wang L, Hong PJMC, Oparin Y, et al. Medical cannabis for chronic non-cancer and cancer related pain: a systematic review and meta-analysis of randomised clinical trials. Br Med J. 2021;n1034. doi:10.1136/bmj.n1034
   PubMedGoogle Scholar
• National Academies of Sciences, Engineering aMWD. The health effects of cannabis and cannabinoids: the current state of evidence and recommendations for research. In: Agenda. Wasahington: National Academies Press (US); 2017.
   Google Scholar
• Busse JW, Vankrunkelsven PZL, Heen A, et al. Medical cannabis and cannabinoids for chronic pain: a clinical practice guideline. Br Med J. 2021;2021:1.
   Google Scholar
• Bhaskar A, Bell A, Boivin M, et al. Consensus recommendations on dosing and administration of medical cannabis to treat chronic pain: results of a modified Delphi process. J Cannabis Res. 2021;3(1):22. doi:10.1186/s42238-021-00073-1
   PubMedGoogle Scholar
• Canada Gd. Cannabis for medical purposes under the Cannabis act: information and improvements; 2021.
   Google Scholar
• Ashton JC. Cannabinoids for the treatment of inflammation. Curr Opin Investig Drugs. 2007;8(5):373–384.
   PubMedGoogle Scholar
• Abuhasira R, Shbiro L, Landschaft Y. Medical use of cannabis and cannabinoids containing products - Regulations in Europe and North America. Eur J Intern Med. 2018;49:2–6. doi:10.1016/j.ejim.2018.01.001
   PubMed Web of Science ®Google Scholar
• Furrer D, Kröger E, Marcotte M, et al. Cannabis against chronic musculoskeletal pain: a scoping review on users and their perceptions. J Cannabis Res. 2021;3(1):41. doi:10.1186/s42238-021-00096-8
   PubMedGoogle Scholar
• Ware MA, Doyle CR, Woods R, Lynch ME, Clark AJ. Cannabis use for chronic non-cancer pain: results of a prospective survey. Pain. 2003;102(1–2):211–216. doi:10.1016/s0304-3959(02)00400-1
   PubMed Web of Science ®Google Scholar
• Beaulieu P, Boulanger A, Desroches J, Clark AJ. Medical cannabis: considerations for the anesthesiologist and pain physician. Can Anesth. 2016;63(5):608–624. doi:10.1007/s12630-016-0598-x
   PubMed Web of Science ®Google Scholar
• Ko GD, Bober SL, Mindra S, Moreau JM, Ko G. Medical cannabis ‒ the Canadian perspective<p class=“MsoNormal”>. J Pain Res. 2016;9:735–744. doi:10.2147/JPR.S98182
   PubMed Web of Science ®Google Scholar
• Rotermann M. Looking back from 2020, how cannabis use and related behaviours changed in Canada. Health Rep. 2021;32:3–14. doi:10.25318/82-003-x202100400001-eng
   PubMed Web of Science ®Google Scholar
• Fishbein M, Ajzen I. Predicting and Changing Behavior: The Reasoned Action Approach. New York: Taylor & Francis; 2011.
   Google Scholar
• Ajzen I. The theory of planned behavior. Organ Behav Hum Decis Process. 1991;50:179–211. doi:10.1016/0749-5978(91)90020-T
   Web of Science ®Google Scholar
• Saunders B, Sim JA-O, Kingstone T, et al. Saturation in qualitative research: exploring its conceptualization and operationalization. Qual Quant. 2018;52:1893–1907. doi:10.1007/s11135-017-0574-8
   PubMed Web of Science ®Google Scholar
• Korn L, Haynie DL, Luk JW, Sita K, Simons-Morton BG. Attitudes, subjective norms, and perceived behavioral control associated with age of first use of Cannabis among adolescents. J Sch Health. 2021;91(1):50–58. doi:10.1111/josh.12977
   PubMed Web of Science ®Google Scholar
• Government of Canada. Cannabis act, SC 2018, c 16; 2018. Available from: https://laws-lois.justice.gc.ca/eng/acts/C-24.5/FullText.html. Accessed 11 October 2023.
   Google Scholar
• Collège des médecins du Québec. Cannabis à des fins médicales: la SQDC n’est pas une option! [Cannabis for medical purposes: the SQDC is not an option!]; 2019.
   Google Scholar
• Collège des médecins du Québec. Ordonnance de cannabis à des fins médicales [Authorization of cannabis for medical purposes]; 2018.
   Google Scholar
• Government of Canada. Cannabis for medical purposes under the Cannabis Act: information and improvements. Ottawa: Health Canada; 2020. Available from: https://www.canada.ca/en/health-canada/services/drugs-medication/cannabis/medical-use-cannabis.html. Accessed 11 October 2023.
   Google Scholar
• Chang Y, Zhu M, Vannabouathong C, Mundi R, Chou RS, Bhandari M. Medical Cannabis for chronic noncancer pain: a systematic review of health care recommendations. Pain Res Manag. 2021;2021:8857948. doi:10.1155/2021/8857948
   PubMed Web of Science ®Google Scholar
• Gardiner KM, Singleton JA, Sheridan J, Kyle GJ, Nissen LM. Health professional beliefs, knowledge, and concerns surrounding medicinal cannabis – a systematic review. PLoS One. 2019;14(5):e0216556. doi:10.1371/journal.pone.0216556
   PubMed Web of Science ®Google Scholar
• Bell RF, Kalso EA. Cannabinoids for pain or profit? Pain. 2021;162(Suppl 1):S125–s6. doi:10.1097/j.pain.0000000000001930
   PubMedGoogle Scholar
• Alexander SPH. Barriers to the wider adoption of medicinal Cannabis. Br J Pain. 2020;14(2):122–132. doi:10.1177/2049463720922884
   PubMed Web of Science ®Google Scholar
• Epstein RM, Street RL. The values and value of patient-centered care. Ann Fam Med. 2011;9(2):100–103. doi:10.1370/afm.1239
   PubMed Web of Science ®Google Scholar
• Turk DC, Wilson HD, Cahana A. Treatment of chronic non-cancer pain. Lancet. 2011;377(9784):2226–2235. doi:10.1016/S0140-6736(11)60402-9
   PubMed Web of Science ®Google Scholar
• Zolotov Y, Metri S, Calabria E, Kogan M. Medical cannabis education among healthcare trainees: a scoping review. Complement Ther Med. 2021;58:102675. doi:10.1016/j.ctim.2021.102675
   PubMed Web of Science ®Google Scholar
• Zeng L, Lytvyn L, Wang X, et al. Values and preferences towards medical cannabis among people living with chronic pain: a mixed-methods systematic review. BMJ open. 2021;11(9):e050831. doi:10.1136/bmjopen-2021-050831
   PubMed Web of Science ®Google Scholar
• Andreae MH, Carter GM, Shaparin N, et al. Inhaled cannabis for chronic neuropathic pain: a meta-analysis of individual patient data. J Pain. 2015;16(12):1221–1232. doi:10.1016/j.jpain.2015.07.009
   PubMed Web of Science ®Google Scholar
• (CACMS) CotAoCMS. CACMS 101: a primer on accreditation of Canadian MD programs by the committee on the accreditation of Canadian medical schools (CACMS) Licensed under CC BY-NC-SA 4.0; 2023. Available from: https://cacms-cafmc.ca/wp-content/uploads/2023/03/CACMS-101-A-Primer-on-CACMS-Accreditation.pdf. Accessed September 29, 2023.
   Google Scholar
• Cannabis IP, Analgesia C. International association for the study of pain presidential task force on cannabis and cannabinoid analgesia position statement. Pain. 2021;162:S1–S2.
   PubMed Web of Science ®Google Scholar
• Barakji J, Korang SK, Feinberg J, et al. Cannabinoids versus placebo for pain: a systematic review with meta-analysis and trial sequential analysis. PLoS One. 2023;18(1):e0267420. doi:10.1371/journal.pone.0267420
   PubMed Web of Science ®Google Scholar
• Pennypacker SD, Cunnane K, Cash MC, Romero-Sandoval EA. Potency and therapeutic THC and CBD ratios: US cannabis markets overshoot. Front Pharmacol. 2022;13:921493.
   PubMed Web of Science ®Google Scholar